How is the Bronchiectasis Radiology Index (Reiff or modified Reiff score) calculated from a high‑resolution CT scan and what do the resulting scores indicate regarding disease severity and management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 1, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Bronchiectasis Radiology Index Score

Understanding the Reiff and Modified Reiff Scoring Systems

The Reiff score (and its modified version) is a semi-quantitative CT scoring system that evaluates three key components: bronchiectasis extent, bronchial wall thickening severity, and bronchial wall dilatation severity across all lung lobes. 1

Components of the Reiff Score

The scoring system evaluates:

  • Bronchiectasis extent: Assessed by counting the number of bronchopulmonary segments affected across all lung lobes 1
  • Bronchial wall thickening severity: Graded on a scale from 0 (none) to 3 (severe) for each anatomical level 2
  • Bronchial wall dilatation severity: Similarly graded from 0 (none) to 3 (severe), taking into account the degree of airways dilatation 2

Calculation Method

The Modified Reiff score is calculated by evaluating each lung lobe separately and then summing the scores across all affected regions. 3 The assessment involves:

  • Examining high-resolution CT (HRCT) scans at standardized anatomical levels 2
  • Scoring each lobe for the presence and severity of bronchiectasis 1
  • Quantifying bronchial wall changes using the 0-3 grading scale 2
  • Summing individual component scores to generate a total score 1

Clinical Significance and Disease Severity Correlation

Radiologic-Clinical Correlations

Higher Modified Reiff scores correlate significantly with worse disease severity markers including lower FEV1, more frequent exacerbations requiring hospitalization, and greater dyspnea symptoms. 3 Specifically:

  • Patients with obstructive ventilatory disorders demonstrate significantly higher Modified Reiff scores [median 6 (IQR 3-10)] compared to those with normal ventilation 3
  • The score correlates with both FACED and Bronchiectasis Severity Index (BSI) scores 3
  • More severe radiologic findings on the Modified Reiff score are associated with more severe lung function impairment 3

Important Clinical Caveat

Normal pulmonary function tests may coexist with significant HRCT abnormalities and elevated Reiff scores, meaning spirometry alone is not an accurate method for assessing bronchial structural damage severity in bronchiectasis. 1 This underscores why radiologic scoring remains essential for comprehensive disease assessment.

Practical Application in Management

When to Use CT Scoring

Non-contrast HRCT with thin-section (1.5 mm) imaging is the reference standard for detecting and quantifying bronchiectasis, as chest radiography is insensitive (up to 34% false-negative rate). 4 The British Thoracic Society recommends HRCT as the examination of choice for evaluating suspected bronchiectasis 2, 4

Prognostic Value

CT findings of bronchiectasis involving ≥3 lobes are associated with poorer outcomes and incorporated into severity scores with high predictive value for exacerbations, hospitalizations, and mortality. 2 The radiologic extent directly influences:

  • Risk stratification for future exacerbations 2
  • Hospitalization rates over 1-4 years 2
  • Mortality predictions 2
  • Treatment eligibility decisions 2

Limitations of the Reiff Score

While the Reiff score provides objective quantification, no semi-quantitative visual scoring system has been shown to be superior to other visual methods, and literature on clinical practice use remains limited. 2 Alternative simplified systems like BRICS (Bronchiectasis Radiologically Indexed CT Score) focus on just two parameters—bronchial dilatation and emphysema extent—and may be more practical for routine clinical use 5

Follow-Up Imaging Strategy

Follow-up HRCT within 12 months is advisable for patients with progressive pulmonary fibrosis or clinical/functional decline; side-by-side comparison with baseline scans is strongly recommended to reduce variability. 2, 6 Multi-planar reconstruction on sagittal and coronal planes should be evaluated to increase diagnostic confidence 2

Related Questions

What investigations are used to diagnose and manage bronchiectasis?
Is a CT scan of the lungs indicated to evaluate for potential bronchiectasis in a patient with a stable, low-density opacity approximately 4 cm in diameter, lateralized to the left, with associated linear opacity on lateral radiograph?
What follow-up care is recommended for incidental findings of mild cylindrical bronchiectasis on a computed tomography (CT) scan of the lungs?
What is the indication for a computed tomography (CT) scan of the chest when bronchiectasis is suspected on a chest X-ray?
What does increased bronchial markings on imaging indicate?
In a postpartum woman with massive obstetric hemorrhage who now has failure to lactate, amenorrhea, fatigue, cold intolerance, hypotension, and signs of hypothyroidism and adrenal insufficiency, what is the likely diagnosis and how should it be confirmed and managed?
What remifentanil infusion rate should be started for a 100‑kg intubated, agitated, hypotensive adult?
How should an asymptomatic patient with persistently elevated serum uric acid be evaluated and managed, including when to start urate‑lowering therapy?
What starting dose and infusion rate of remifentanil should be used for a 100‑kg intubated, agitated, hypotensive adult when one 5‑mg (5000‑µg) vial is diluted in 100 mL normal saline?
Is a urine protein concentration of 9.4 mg/dL, urine creatinine of 85.9 mg/dL, and protein‑to‑creatinine ratio of 0.11 considered normal?
What is the appropriate diagnostic work‑up for a patient with suspected amyloidosis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.